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Abstract
Measurement of vessel caliber by Magnetic Resonance Imaging (MRI) is a valuable technique for
in vivo monitoring of hemodynamic status and vascular development, especially in the brain.
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Here, we introduce a new paradigm in MRI coined as Vessel Architectural Imaging (VAI) that
exploits an intriguing and overlooked temporal shift in the MR signal forming the basis for vessel
caliber estimation and show how this phenomenon can reveal new information on vessel type and
function not assessed by any other non-invasive imaging technique. We also show how this
biomarker can provide novel biological insights into the treatment of cancer patients. As an
example, we demonstrate using VAI that anti-angiogenic therapy can improve microcirculation
and oxygen saturation levels and reduce vessel calibers in patients with recurrent glioblastomas,
and more crucially, that patients with these responses have prolonged survival. Thus, VAI has the
potential to identify patients who would benefit from therapies.
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INTRODUCTION
Anti-angiogenic therapeutic agents target solid tumors by vessel pruning and normalization
of vascular structure and function thereby contributing to improved outcome of
simultaneously administered chemo-, radiation- and immuno-therapies1–3. In a trial using
cediranib, an oral pan-VEGF (vascular endothelial growth factor) receptor kinase inhibitor4,
patients with recurrent glioblastomas whose tumor perfusion increased during treatment
survived approximately 6 months longer compared to those whose perfusion did not
increase5. Although promising, the exact microvascular mechanism by which these drugs
increase perfusion and subsequently improve survival in patients is not fully understood. In
the brain, magnetic resonance imaging (MRI) is the modality of choice for soft tissue
imaging in vivo. In addition to measures of perfusion and blood volume, newer MRI
techniques can estimate microvascular vessel caliber, thereby providing further insight into
tissue microvascularity6–9. Vessel caliber is estimated by comparing the changes in observed
proton relaxation from simultaneously acquired contrast agent-enhanced gradient-echo and
spin-echo MRI6, 7, 9. The gradient-echo and spin-echo readouts have different sensitivity to
the so-called susceptibility effect, the magnetization induced in a medium when exposed to a
magnetic field and the highly susceptibility-sensitive gradient-echo images are sensitive to
both microscopic and macroscopic vessels, whereas spin-echo images are predominantly
sensitive to microscopic vessels (radius < 10 μm)7, 10, 11.
Here we build on this concept and exploit an overlooked temporal shift in the MR signal that
forms the basis for vessel caliber estimation and have coined the technique Vessel
Architectural Imaging (VAI). In practice, cerebral vessel caliber by MRI is assessed using
the quotient of gradient-echo to spin-echo blood volume or direct assessment of the point-
by-point difference in the contrast agent-enhanced relaxation rate curves4, 9, 12, 13. However,
depending on the hemodynamic properties of the tissue, the different sensitivities of the
gradient-echo and spin-echo images to the susceptibility effect will result in an apparent
variation in the respective MRI signal readouts (Fig. 1a–d). The outcome of this is a relative
shift in the shapes and peak positions of the two relaxation rate curves. When visualized in a
parametric plot, depending on tissue type, the pair-wise gradient-echo and spin-echo data
points may form a vortex curve of a certain shape and transverse in a clockwise or counter-
clockwise direction9.
The origin of this phenomenon, its exact relationship to the underlying tissue and its
implication for imaging in cancer patients have not been described to date. Here, we first
illustrate the power of the VAI technique in a range of vessel types under different
conditions by using Monte Carlo simulations and then show data from subjects with
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recurrent glioblastomas. Using VAI, we found that anti-angiogenic therapy led to a
reduction in tumor vessel calibers, improved hemodynamic efficiency and oxygen saturation
levels, and more importantly, that subjects with these responses had prolonged survival.
RESULTS
Intravascular magnetic susceptibility perturbations in VAI
To gain insight into the VAI technique for different vessel types and calibers, we conducted
Monte Carlo simulations to derive parametric vessel vortex curves for physiologically
meaningful capillary vessels of 3.5 μm radius and non-capillary vessels with radii ranging
from 7.5 μm to 40 μm (Fig. 2). Note that the vessel vortices transverse in a counter-
clockwise direction if, and only if, the vascular system contains both slow inflow, larger-
caliber venule-like vessel components and faster inflow, smaller-caliber arteriole-like or
capillary-like vessel components. In contradistinction, if the vascular system consists of
arterioles and capillaries only – or, for some geometrical, pathological or physiological
reason, fast inflow arterioles with larger calibers than venules8, 14 - the vessel vortices
transverse in a clockwise direction. For vessels of identical calibers, because of differences
in tissue-specific oxygen saturation (SO2) levels15, 16, the vessel vortices transverse in a
counter-clockwise direction if both arterioles and venules are included. However, if all
vessels have identical calibers and SO2 levels, there is no vortex (shown for capillaries in
Fig. 2). Similarly, if a vascular system with a fixed SO2 level contains arterioles, capillaries
or venular structures only, there is no vortex - even if the vessels have different radii
(Supplementary Fig. 1a).
The shape of the vessel vortex curve depends not only on the vessel types included, but also
on their relative difference in vessel radius as discussed below (Supplementary Fig. 1b–c).
The slope of the vortex curve is assumed proportional to the vessel caliber, and tilted
towards the gradient-echo axis for vascular systems with larger average vessel calibers9. We
provide a schematic illustration of the VAI analysis procedure, including an explanation of
how the various parameters are derived from the vessel vortex curves (Supplementary Fig.
2).
VAI response to changes in volume fraction and SO2 levels
We used Monte Carlo simulations to gain insight into the VAI technique for different blood
volume fractions (Vf ~ blood volume, Fig. 1c–d), and for varying levels of SO2. Increased
Vf by vessel recruitment (Supplementary Fig. 3a) results in; a proportional increase in the
length of the long axis of the vessel vortex curve16 (Supplementary Fig. 4a), exponential
decrease in slope value (Supplementary Fig. 4d) and a proportional increase in the corrected
vessel vortex area (Supplementary Fig. 4g). For vessel distention (Supplementary Fig. 3b)
similar, although less pronounced effects are observed (Supplementary Fig. 4b,e,h). The
only exception is an exponential increase in slope value with increased Vf for tissue without
functioning or missing capillary vessels or for vessel shunting. The vessel vortex direction
was not affected by the induced changes in vessel recruitment nor distention.
The resulting vessel vortex curves for varying levels of SO2 were assessed using different
combinations of arterioles, capillaries and venules (Fig. 3a,b). Here, the length of the long
axis and the slope of the vessel vortex curve increase with increasing levels of deoxygenated
blood (Supplementary Fig. 4c,f). In a vascular system with relatively unchanged or fixed
vessel calibers and inflow rates, the corrected vessel vortex area reflects the different
baseline susceptibility states in oxygenated and deoxygenated blood and thus SO2 levels.
Here, under normal conditions (venule calibers > arteriole calibers), the corrected vessel
vortex area shows a Gaussian, bell-shaped response to changes in SO2 levels
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(Supplementary Fig. 4i) expressed by an increase in the corrected vessel vortex area for
increased absolute differences in SO2 levels between well-saturated, oxygenated arterioles
(SO2 > 90%) and deoxygenated capillaries and venules (SO2 < 90%). Correspondingly, for
anoxic SO2 levels and towards a theoretical and fully deoxygenated hemodynamic
environment (arterioles; SO2 < 75%, capillaries and venules; SO2 = 0%), the corrected
vessel vortex area decreases.
Improved tumor microcirculation prolong survival
We show a clinical application of VAI by retrospective analysis of 30 human subjects with
recurrent glioblastomas enrolled in a Phase II clinical trial of cediranib4, 17. Collectively, a
significant increase (pair-wise Wilcoxons Signed Ranks test; P < 0.05) in the relative
number of image voxels with a clockwise vortex direction in the tumor after therapy onset
was observed thereby mimicking normal-appearing tissue values (Supplementary Fig. 5a
and Supplementary Table 1). A more dominant effect was seen in the tumor center (pair-
wise Wilcoxons Signed Rank test; P < 0.01) compared to the tumor edge (Supplementary
Fig. 5b). Ten subjects were identified as responders to the anti-angiogenic therapy by a
relative increase in image voxels with a clockwise vortex direction compared to the
arithmetic mean of all subjects, and at a minimum of two consecutive imaging time points
(Fig. 4a–d and Supplementary Fig. 5c). Twelve subjects were identified as non-responders
by a relative decrease in image voxels with a clockwise vortex direction (Supplementary
Figs. 6 and 5d).
Median overall survival for responding subjects was 341 d compared to 146 d for non-
responders (Fig. 5a–c). Using Cox regression with time dependent covariates, the relative
increase in clockwise vessel vortices during anti-angiogenic therapy was an independent
predictor of progression-free survival and overall survival (P < 0.01) and also reflected in
significant reductions in the contrast enhanced and FLAIR tumor volumes at day 28 (Mann-
Whitney tests; P < 0.05; Supplementary Fig. 7a,b). In addition to Vf, no differences in vessel
calibers, permeability, spin-echo and gradient-echo perfusion (flow) or spin-echo and
gradient-echo mean transit times were observed between the two groups (Supplementary
Fig. 7c–h). For responding subjects and compared to pre-treatment, significant reductions in
whole-tumor vessel calibers (pair-wise Wilcoxons Signed Rank test; P < 0.01) and
subsequent reductions in Vf and corrected vessel vortex area in the tumor center were
observed (pair-wise Wilcoxons Signed Rank tests; P < 0.01). Reproducibility analysis
showed minimal variability (Supplementary Fig. 5e,f).
DISCUSSION
Assessment of the topological and structural heterogeneity of tumor microcirculation is
important for monitoring of disease progression and treatment response. Tumor vessels are
characterized by increases leakiness and regional, inefficient closed or blind vascular
pathways with or without hypoxia2, 18–22. The VAI technique described in our study is
capable of measuring these effects in vivo, ranging from well-functioning, well-oxygenated
normal-appearing tissue to the vascular collapse observed in anoxic tumor tissue. Our results
provide several new insights. Overall, the temporal shift in the MR signal can be readily
observed with a standard combined gradient-echo and spin-echo contrast enhanced MRI
acquisition technique. In normal tissue, the resulting vessel vortex curve propagates in a
counter-clockwise direction if large, slow inflow vessels and faster inflow vessels with
smaller calibers are present. The slope of the vessel vortex curve is indeed influenced by the
average vessel caliber of the tissue9, but the traditional view of increasing slope values for
bigger vessel calibers is dependent on changes in Vf and SO2 levels. The highest slope
values were observed for theoretical vessel systems with local shunting, where big
disorganized, fast-flow arterioles aberrantly connect to disorganized venous structures19, 23.
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Contrary to vascular systems with functioning capillaries, local shunting will also depict a
relatively constant corrected vessel vortex area indicative of little or no difference in oxygen
saturation between the tissue types.
The subnormal vascular function and non-uniform branching hierarchy of recurrent
glioblastomas2, 20 was identified by a higher relative ratio of larger-caliber, deoxygenated
venule-like vessel compared to other vessel types. This was more pronounced towards the
tumor center and in line with a vascular gradient moving from a neoangiogenic tumor border
of normal- or dilated vessels towards a hypoxic or anoxic core with scarce, inefficient and
very large vessels1, 22, 24. During anti-angiogenic therapy, a higher ratio of image voxels
with a clockwise vortex direction was observed in responding subjects, mimicking the ratio
seen in normal-appearing tissue. This change in vessel vortex direction requires a higher
quantity of vessels with fast inflow rates combined with a reduction of large vessels with
slow inflow. This is consistent with data from studies in animal and human solid tumors
where proper doses of anti-angiogenic drugs lead to improved tumor microenvironment and
more effective delivery of exogenously administered therapeutics by reduced tumor
hyperpermeability and vessel calibers, hypoxia and interstitial fluid pressure and increased
vascular pericyte coverage2, 5, 25–27. Correspondingly, the improved microcirculation
identified by the VAI technique was predictive of progression-free survival and overall
survival. Interestingly, although perfusion plays a key role in the response to therapy5,
average perfusion values alone could not explain the observed difference between
responders and non-responders. This is in line with previous work showing that changes in
perfusion are not likely to have a substantial influence on the relaxation rate curves7 (i.e.
vessel vortex curves) and indicates that VAI is a different and potentially more sensitive
biomarker than traditional MRI. This may, in part, be explained by the VAI’s apparent
sensitivity to changes in SO2 levels. For responding subjects at day one of treatment, the
average vessel vortex curve slope did not increase even though the average Vf decreased –
which at a hypothetical fixed SO2 level should have resulted in an increased slope value
(Supplementary Fig. 4d–f). This suggests that anti-angiogenic therapy improves and
normalizes oxygen concentrations thereby providing benefit to these subjects2, 19, 23, 27.
In summary, while traditional MRI of cancer in vivo is confounded by haphazard and
heterogeneous vessel architecture with limited or redundant perfusion, the VAI technique
exploits these properties and provides further insights into the complex nature of tumor
vascularity.
ONLINE METHODS
Monte Carlo simulations
We performed Monte Carlo simulations in Matlab (MathWorks) to assess variations in
transverse relaxation rates for the gradient-echo and spin-echo signals as a function of
contrast agent concentration and microvascular structure. The general theory behind the
relaxation rate simulations has been previously described7. In short, the intravascular
fraction of tissue is approximated by randomly oriented water impermeable cylinders with a
defined blood volume fraction (Vf), radius (R), water diffusion (D) and susceptibility
difference (Δχ) between the intra-cylindrical and extra-cylindrical space. Vessels were
modeled as infinite cylinders under the assumption that the average proton diffusion length
during the observation time, equal to the echo-time (TE) of the respective gradient-echo and
spin-echo sequences, is much shorter than the typical vessel segment length. The z-
component of the magnetic field perturbation of the external magnetic field B0 (oriented
along the horizontal z-axis of the MR magnet) due to each segment can then be
approximated by:
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(1)
where θ is the angle between B0 and the cylinder axis and (ϕ, r) are the polar coordinates of
the proton location relative to the projection of B0 in a plane orthogonal to the cylinder axis.
A single proton was placed at the origin of the closed simulation space and allowed to
randomly diffuse in a plane orthogonal to B0 through the intra- or extra-cylindrical space
with total diffusion duration equal to the echo-time. The random walk was simulated by
arbitrarily changing the orientation of the spin every 0.1 ms using a Gaussian displacement
distribution (with mean; μ = 0 and variance; ) along the orthogonal directions at
each time step. The magnetic field perturbation at the proton position from a predefined set
of cylinders, and the corresponding phase shift, were recorded every 0.5 ms. This procedure
was repeated for n = 5000 protons and the complex signal due to the accumulated phase of
all protons were defined as:8
(2)
where φn (t) is the phase of the n-th proton at time t. The proton phase accumulated during a
time step from the presence of each cylinder was given by Δφn (t) = γΔBzΔt, where γ is the
gyromagnetic ratio.
For estimations of Δχ as a function of contrast agent concentration, the baseline magnetic
susceptibility of fully oxygenated blood and tissue was assumed to be equal and Δχ directly
proportional to [C]χGd, where [C] is the intravascular gadolinium concentration and χGd =
0.32*10−6 mM−1 as previously shown28. The transverse relaxation effect due to
deoxygenated blood was modeled by inclusion of an additional intra- and extra-vascular
susceptibility difference in the resulting arterial, capillary and venous relaxation rate curves
which could be varied between ΔχdHb = 2.5*10−6 for fully deoxygenated blood and ΔχdHb =
0 for fully oxygenated blood16, 29. The relationship between arteriole and venule brain
hematocrit were considered linear for our data and thus negligible30. The corresponding
change in relaxation rate (shown for gradient-echo) was estimated by assuming a mono-
exponential signal decay as a function of diffusion time:
(3)
where | | is the modulus of the signal. For estimation of spin-echo relaxation rate changes,
the phase dispersion was inverted at t = TE/2 to account for the refocusing effect of the 180
° radio frequency pulse. The spin-echo signal decay was then similarly measured at time TE
and converted to the corresponding change in relaxation rate according to equation [3]. The
effect of red blood cell velocity combined was not included in our simulations. Unlike
normal tissue, blood velocities in tumor do not strictly depend on vessel calibers31.
However, previous simulations suggest that the effect of red blood cell velocity is expected
to be equal for the gradient-echo and spin-echo relaxation rate curves with minimal variance
for changes in velocity about or above physiologic capillary velocities7 (≥ 0.2 cm s−1).
Furthermore, it should be noted that the random walk model is limited in that it only
simulates relaxation effects due to proton diffusion orthogonal to the external magnetic field
and does not model the full effect of three-dimensional displacements. However, given the
random orientation of capillaries, the induced relaxation effect can be assumed to be
independent of z-position (position along B0) and the two-dimensional model has previously
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been shown to provide relaxation rate estimates in very good agreement with in vivo data
obtained with an intravascular contrast agent in a rat model7.
Representative relaxation rate curves following a simulated contrast agent injection (similar
to the curves in Fig. 1c–d) were estimated by coupling the resulting gradient-echo and spin-
echo relaxation rates at physiologically meaningful values of Vf, radius and water
diffusion32 to synthetic and typical arterial, capillary and venous shaped curves using JSim
(National Simulation Resource Physiome initiative)33. Parametric vessel vortex curves were
derived by point-by-point parametric plots of the gradient-echo and spin-echo relaxation rate
curves (Fig. 1c–d and Supplemental Fig. 2)9, 34. The effect of contrast agent extravasation
due to disrupted blood-brain-barrier was assumed negligible or corrected for.
Human subjects
The study was approved by the institutional review board and informed consent was
obtained from all subjects17. Subject data included 13 females and 17 males diagnosed with
a recurrent glioblastoma, average age 52 years, range 20–78 years. After study termination,
nine subjects received one subsequent cycle of salvage chemotherapy, eight subjects
received two cycles, one subject received three cycles, two subjects had undisclosed
information on salvage chemotherapy and one subject received stereotactic radiosurgery.
MRI acquisition
Baseline MRI examinations were acquired prior to therapy onset (days −5 and −1), and then
repeated on days 1, 28, 56 and 112 after cediranib (AstraZeneca Pharmaceuticals) anti-
angiogenic therapy onset or until disease progression according to the Macdonald
criteria4, 35. All imaging were performed on a 3 Tesla Magnetom Trio MRI system (Siemens
Medical Solutions) as follows:
1. T1-weighted images. Axial images acquired prior to, and after, contrast agent
injection (gadopentetate-dimeglumine, Gd-DTPA, Magnevist, Bayer Schering
Pharma AG). Repetition-time 600 ms, echo-time 12 ms, slice-thickness 5 mm,
inter-slice distance 1 mm, in-plane resolution 0.45:0.45 mm, matrix size 384:512
and 23 slices.
2. T2-weighted (FLAIR) images. Axial images with repetition-time 10 s, echo-time 70
ms, slice-thickness 5 mm, inter-slice distance 1 mm, in-plane resolution 0.60:0.45
mm, matrix size 384:512 and 23 slices.
3. Dynamic contrast enhanced (DCE) images. Axial, fast gradient-echo images with
repetition-time 5.7 ms, echo-time 2.73 ms, slice-thickness 2.1 mm, inter-slice
distance 0.4 mm, in-plane resolution 2.90:2.00 mm, matrix size 128:87 and 20
slices. After approximately 52 s of imaging, a 0.1 mmol kg−1 dose of Gd-DTPA
was injected at 5 cc s−1. Also, spoiled gradient recalled-echo images with five
different flip angles (2, 5, 10, 15 and 30 °) were initially acquired for T1-mapping.
4. Dynamic susceptibility contrast (DSC) perfusion images. Axial dual-echo echo-
planar images with repetition-time 1.33 s, echo-times 34 ms and 103 ms, slice-
thickness 5 mm, inter-slice distance 2.5 mm, in-plane resolution 1.70:1.70 mm,
matrix size 128:128, 10 slices and 120 volumes. After approximately 85 s of
imaging, a 0.2 mmol kg−1 dose of Gd-DTPA was injected at 5 cc s−1.
MRI post-processing
An experienced neuroradiologist identified tumor by outlining enhancing regions on the
contrast-enhanced T1-weighted images and peritumoral vasogenic edema on the FLAIR
images4. The anatomical MR images were realigned to the DSC and DCE images using
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normalized mutual information coregistration. On the T1-weighted tumor outlines, areas
corresponding to the tumor center and edge were derived using three-dimensional
connectivity morphologic analysis in Matlab where an image voxel was assumed to be a
center voxel if all neighboring cubical voxels were also outlined as tumor.
The DCE data were processed using custom-made software in Matlab, applying standard
approaches to create Ktrans maps4, a measure of the permeability that roughly corresponds to
wash-in rates of the contrast agent in tissue.
We obtained relaxation rate curves for VAI analysis, perfusion values, blood volumes and
mean transit times using established tracer kinetic models on the DSC images, corrected for
contrast agent leakage (from blood-brain-barrier breakdown or resection)36 and fitted to a
gamma-variate curve for better visualization of vessel vortex effects. It has been speculated
that contrast agent leakage is the reason for the clockwise vortex effect9. Not correcting for
leakage resulted in an average 5% drop in the clockwise to counter-clockwise vortex
direction ratio with minimal influence on our results. Here, the pre-dose of Gd-DTPA during
DCE imaging saturated potential leaky tumor tissue in the DSC images thereby minimizing
the influence of leakage-induced T1-shortening effects. Relaxation rate curves not suited for
analysis, conveying highly fluctuating time-courses from partial volume effects, voxel shifts
and physiological pulsations were excluded from further analysis. Across all 30 subjects, an
average of 78.21% ± 12.78% (standard deviation) of all tumor voxels met the inclusion
criteria. To account for potential global systemic effects from hypertension, tumor relaxation
rate curves were scaled with corresponding slice-specific mean, normal-tissue reference
curves. In all figures showing vessel vortex curves, the tails of the vortex curves have been
cut short to better visualize vortex direction. VAI analysis was performed using custom-
made software in Matlab and traditional MRI was analyzed in nordicICE (NordicNeuroLab
AS).
Statistical analysis
A subject was assumed to have an increase (decrease) in voxels with a clockwise vortex
direction if the clockwise- to counter-clockwise ratio was higher (lower) than the 95%
confidence interval of the population arithmetic mean for two consecutive imaging time
points. Subjects who did not meet this criterion were treated as having no change in vortex
direction ratio. Differences in VAI parameters during therapy were assessed using pairwise
Wilcoxons Signed Rank test. Differences in tumor volumes, vessel caliber, permeability,
perfusion and mean transit times were assessed using Mann-Whitney tests. Associations
between changes in vessel vortex direction ratios and progression-free survival and overall
survival were assessed using multinomial logistic regression, Kaplan-Meier survival
analysis and Cox regression after adjustments for age, extent of resection, neurological
performance, salvage chemotherapy and stereotactic radiosurgery after study termination as
well as changes in permeability (Ktrans), T1-weighted contrast-enhanced tumor volume and
T2-weighted FLAIR tumor volume prior to, and during, anti-angiogenic therapy. For all
tests, P = .05 was considered significant (with Holm-Bonferroni correction for multiple
comparisons) and pixel values below a 5% percentile and above a 95% percentile were
removed prior to analysis to reduce the influence of outliers. Reproducibility tests were
assessed using Spearman Rank correlations and Bland-Altman plots. Statistical analysis was
performed using SPSS 17 (SPSS Inc.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Vessel architectural imaging in a healthy volunteer. Simultaneously acquired (a) gradient-
echo (GE) and (b) spin-echo (SE) contrast enhanced relaxation rate images showing the
gradient-echo and spin-echo MR signals peaking at different image readouts during the
contrast agent bolus passage. Typically, in areas with fast inflow of the contrast agent, such
as in the feeding branches of the middle cerebral artery (red arrows), the gradient-echo
signal peaks earlier than the spin-echo signal resulting in a clockwise vortex when plotting
the relaxation rate curves in a point-by-point parametric plot (c). Correspondingly, in slow
inflow areas, for example in the venules leading to the internal cerebral veins (blue arrows),
the spin-echo signal peaks earlier than the gradient-echo signal resulting in a counter-
clockwise vortex (d). The contrast agent-induced relaxation rates in (c–d) are scaled relative
to their baseline rates (prior to contrast agent arrival), and will increase and decrease with a
full-width half-maximum proportional to the mean transit time. Volume fraction (Vf) is
defined as the area under the relaxation rate curves (percentage of blood in the image voxel
~ blood volume), whereas perfusion (~ flow) can be estimated using the central volume
principle stating that Vf is the product of flow and mean transit time.
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Figure 2.
Parametric vessel vortex curves for different vessel combinations. Monte Carlo simulation
showing the resulting point-by-point parametric vessel vortex curves from the gradient-echo
(GE) and spin-echo (SE) relaxation rate curves following a theoretical contrast agent
injection at different combinations of vessel radii and type. The vessel vortex curves vary in
size, shape and direction (clockwise versus counter-clockwise) depending on the
combination of vessel type and caliber. For vortex direction, a counter-clockwise vortex is
observed only if slower inflow, venule-like vessels with larger calibers than the other vessel
components (arterioles or capillaries) are included in the system. Compared to arterioles,
healthy venules are typically characterized by larger vessel calibers with longer mean transit
times and slower inflow. For all vessel combinations, Vf was kept at 3.5%, where an
increase in vessel caliber (distension) implies a subsequent reduction in vessel density
(negative recruitment). The SO2 levels were kept at normal values (arterioles at 90 – 95%,
capillaries and venules at 50%)15, 16.
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Figure 3.
Responses in parametric vessel vortex curves to changes in oxygen saturation. Monte Carlo
simulations showing resulting parametric vessel vortex curves for a uniform system of
arterioles (R = 10 μm), capillaries (R = 3.5 μm) and venules (R = 10 μm) from changes in
SO2 levels (Vf fixed at 3.5%). In (a), the SO2 levels in the arterioles are kept at 93% with
capillary- and venule SO2 levels ranging from 93% (no consumption, i.e. from local
shunting) to 0% (full consumption). In (b), the SO2 levels in the arterioles range from 93%
to 0% with capillaries and venules SO2 levels fixed at 0%. Note that the slope, as would be
identified by a linear fit of the vessel vortex curve and historically used as a measure
proportional of vessel caliber9, is higher in (b) compared to (a) at pathologic levels of SO2
even though the vessel caliber is unchanged (shown for 0% - 0% and 93% - 93%,
respectively, with trend lines indicating no vortex curves). (GE = gradient-echo, SE = spin-
echo).
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Figure 4.
Parametric vessel vortex curves of a responding subject with recurrent glioblastoma. (a)
Contrast agent enhanced MRI (T1-weighted) at baseline (days −5 and −1) and during anti-
angiogenic therapy (days 1, 28, 56 and 112). (b) Contrast enhancing tumor regions outlined
on MRI showing tumor center (blue) and tumor edge (red). (c) Vessel caliber MRI. (d)
Corresponding average vessel vortex curves from all pair-wise gradient-echo (GE) and spin-
echo (SE) relaxation rate curves in the tumor center (blue vortex curves) and tumor edge
(red vortex curves). Following anti-angiogenic drug administration, the contrast agent-
enhanced tumor area recede while the average vessel vortex direction change from being
predominantly counter-clockwise at baseline to a clockwise vortex direction during
treatment (days 1 and 28), before reversing at day 56. This effect is most prominent in the
tumor center and the subject was identified as a responder to the anti-angiogenic therapy by
a relative increase image voxels with a clockwise vortex direction compared to the
arithmetic mean of all subjects. (GEref, SEref = scaled to GE and SE reference curves,
respectively).
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Figure 5.
Vessel architectural imaging during anti-angiogenic therapy in subjects with recurrent
glioblastomas. (a) Example anatomical MRI and VAI of a subject with recurrent
glioblastoma at baseline (day −1) and at day 28 after therapy onset. The images show (top-
to-bottom); anatomical contrast enhanced T1-weighted images, volume fraction maps,
vessel caliber maps, vessel vortex area maps and vessel vortex direction maps, respectively.
At baseline, larger vessel calibers are observed in the tumor center compared to the tumor
edge, with low oxygen extraction (low vessel vortex area values) and few voxels with a
clockwise vessel vortex direction. (b) Corresponding vessel architecture in tumor edge,
tumor center and reference tissue at baseline and day 28, respectively. The resulting vessel
structures are based on average values from all 30 subjects, including vessel caliber, Vf,
vessel vortex direction and vessel vortex area (Supplemental Table 1). Responding subjects
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(n = 10) show a move towards a more competent microcirculation during therapy identified
by a relative increase in image voxels with a clockwise vessel vortex direction in the tumor
center, with reduced vessel calibers and improved SO2 levels. Similar to normal tissue, red-
to-violet-to-blue colors indicate normal appearing arteriole, capillary and venule
hemodynamic status, respectively. (c) Kaplan-Meier survival curves show prolonged
survival for responding subjects (median PFS = 153 d, OS = 341 d) compared to non-
responding subjects (n = 12; median PFS = 64 d, OS = 146 d), the latter identified by a
relative decrease in voxels with a clockwise vessel vortex direction.
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